Vir Biotechnology showed strong results in a study, greatly reducing the virus in patients with liver disease.

Nov 9, 2026, 10:23 AM ETTrialRead the original at Benzinga

Good for VIR

Vir's treatment met its main study goal, and 79% of treated patients had no detectable virus at Week 48. Results from 2 more studies are still needed before the planned U.S. filing in 2027.

VIR · Vir Biotechnology Inc.

AI read · Good for VIR

The AI's read

These findings give Vir stronger evidence that its treatment can control a serious infection. No one stopped treatment, and one temporary blood-cell drop resolved within 15 days. Two more studies must report results before the company can submit its planned U.S. filing in 2027.

Get alerts for VIR

Follow Vir Biotechnology Inc. (VIR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VIR

Free on the App Store and Google Play, or on the web.